Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Beksac, Meral; Seval, Guldane Cengiz; Paydas, Semra; Tuglular, Tulin Firatli; Arslan, Onder; Goker, Hakan; Kaynar, Leylagul; Altuntas, Fevzi; Atalay, Figen; Teke, Havva Uskudar; Bolaman, Ali Zahit; Pehlivan, Mustafa; Sonmez, Mehmet; Demir, Ahmet Muzaffer; Topcuoglu, Pervin; Yilmaz, Mehmet; Kapukcu, Sibel Hacıoglu; Albayrak, Murat; Yurttas, Nurgul Ozgur; Salihoglu, Ayse; Cakar, Merih Kizil; Gurman, Gunhan
URI: https://doi.org/ 10.1016/j.clml.2019.09.402
http://openaccess.sanko.edu.tr/xmlui/handle/20.500.12527/412
Date: 2019

Show full item record

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Gazimuhtar Paşa Bulvarı
No:36
27090
Şehitkamil / GAZİANTEP